Medline has signed a definitive agreement to buy NAMIC’s fluid management business from AngioDynamics for $167.5m.

The portfolio comprises a variety of solutions for cardiac catheterisation. The acquisition includes the NAMIC brand, contrast management and closed fluid systems, guidewires, disposable transducers and interventional accessories.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AngioDynamics will also sell its manufacturing facility at Glens Falls, New York. This includes associated manufacturing, sales and marketing teams that support the NAMIC business.

AngioDynamics expects the divestiture to drive investments in other therapeutic areas such as oncology and thrombus management.

“Medline’s scale and extensive kitting operations are sure to drive more momentum for NAMIC products.”

AngioDynamics president and CEO Jim Clemmer said: “Over the past three years, we have streamlined our manufacturing operations and made significant improvements to our research and development (R&D) process, enabling us to develop high-quality, innovative medical devices for our customers.

“These actions, combined with our ongoing portfolio optimisation efforts, including today’s announced transaction with Medline, provide us with the foundation to drive sustainable and increased top-line growth and deliver high-quality new therapies that address unmet patient needs.”

AngioDynamics intends to use around $160m of net cash proceeds from the transaction to pay outstanding debt, while the remaining amount will be used for strategic investments in its existing portfolio.

Medline believes that the NAMIC business will complement its existing medical devices and supplies portfolio.

Medline CEO Charlie Mills noted: “Medline’s scale and extensive kitting operations are sure to drive more momentum for NAMIC products and deliver opportunities for efficiency for customers.”

The transaction is subject to customary closing conditions. After completion, Medline intends to continue manufacturing operations at AngioDynamics’ Glens Falls facility.